ZAI LAB LIMITED Cost of Revenue
ZAI LAB LIMITED (ZLAB) reported Cost of Revenue of $33.62 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2024-05-08
- ZAI LAB LIMITED cost of revenue for the quarter ending 2024-03-31 was $33.62M, a 57.56% increase year-over-year.
- ZAI LAB LIMITED cost of revenue for the quarter ending 2023-12-31 was $25.24M, a 20.61% increase year-over-year.
- ZAI LAB LIMITED cost of revenue for the quarter ending 2023-09-30 was $25.48M, a 27.12% increase year-over-year.
- ZAI LAB LIMITED cost of revenue for the quarter ending 2023-06-30 was $23.76M, a 36.51% increase year-over-year.
- ZAI LAB LIMITED cost of revenue for fiscal 2023 was $95.82M, a 29.45% increase from fiscal 2022.
- ZAI LAB LIMITED cost of revenue for fiscal 2022 was $74.02M, a 41.69% increase from fiscal 2021.
- ZAI LAB LIMITED cost of revenue for fiscal 2021 was $52.24M, a 212.14% increase from fiscal 2020.
- ZAI LAB LIMITED cost of revenue for fiscal 2020 was $16.74M, a 346.41% increase from fiscal 2019.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month | Cost of Revenue 12 month as first filed |
|---|---|---|---|---|---|
| 2024-03-31 | $33.62M 10-Q · filed 2024-05-08 | $58.86M derived: sum of 2 quarters · filed 2024-05-08 | $84.33M derived: sum of 3 quarters · filed 2024-05-08 | $108.10M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2023-12-31 | $25.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $50.72M derived: sum of 2 quarters · filed 2024-02-27 | $74.48M derived: sum of 3 quarters · filed 2024-02-27 | $95.82M 10-K · filed 2024-02-27 | |
| 2023-09-30 | $25.48M 10-Q · filed 2023-11-07 | $49.24M derived: sum of 2 quarters · filed 2023-11-07 | $70.58M 10-Q · filed 2023-11-07 | $91.50M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2023-06-30 | $23.76M 10-Q · filed 2023-08-07 | $45.10M 10-Q · filed 2023-08-07 | $66.02M derived: sum of 3 quarters · filed 2024-05-08 | $86.07M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2023-03-31 | $21.34M 10-Q · filed 2024-05-08 | $42.26M derived: sum of 2 quarters · filed 2024-05-08 | $62.30M derived: sum of 3 quarters · filed 2024-05-08 | $79.71M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $20.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $40.97M derived: sum of 2 quarters · filed 2024-02-27 | $58.38M derived: sum of 3 quarters · filed 2024-02-27 | $74.02M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $20.04M 10-Q · filed 2023-11-07 | $37.45M derived: sum of 2 quarters · filed 2023-11-07 | $53.09M 10-Q · filed 2023-11-07 | $74.80M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $17.41M 10-Q · filed 2023-08-07 | $33.05M 10-Q · filed 2023-08-07 | $54.75M derived: sum of 3 quarters · filed 2024-02-27 | $66.92M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $15.64M 10-Q · filed 2023-05-09 | $37.35M derived: sum of 2 quarters · filed 2024-02-27 | $49.51M derived: sum of 3 quarters · filed 2024-02-27 | $60.38M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $21.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $33.87M derived: sum of 2 quarters · filed 2024-02-27 | $44.73M derived: sum of 3 quarters · filed 2024-02-27 | $52.24M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $12.16M 10-Q · filed 2022-11-09 | $23.03M derived: sum of 2 quarters · filed 2022-11-09 | $30.54M 10-Q · filed 2022-11-09 | $37.36M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $10.87M 10-Q · filed 2022-08-09 | $18.37M 10-Q · filed 2022-08-09 | $25.20M derived: sum of 3 quarters · filed 2023-03-01 | $30.13M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $7.50M 10-Q · filed 2022-05-10 | $14.33M derived: sum of 2 quarters · filed 2023-03-01 | $19.26M derived: sum of 3 quarters · filed 2023-03-01 | $22.16M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $6.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $11.76M derived: sum of 2 quarters · filed 2023-03-01 | $14.65M derived: sum of 3 quarters · filed 2023-03-01 | $16.74M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $4.93M 10-Q · filed 2021-11-09 | $7.83M derived: sum of 2 quarters · filed 2021-11-09 | $9.91M 10-Q · filed 2021-11-09 | $11.49M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $2.90M 10-Q · filed 2021-08-09 | $4.98M 10-Q · filed 2021-08-09 | $6.56M derived: sum of 3 quarters · filed 2022-03-01 | $7.85M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $2.08M 10-Q · filed 2021-05-10 | $3.66M derived: sum of 2 quarters · filed 2022-03-01 | $4.95M derived: sum of 3 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $1.58M derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01 | $2.87M derived: sum of 2 quarters · filed 2022-03-01 | $3.75M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $1.29M derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | $2.17M 6-K · filed 2020-01-21 | |||
| 2019-06-30 | $882.00K 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | $43.00K 10-K · filed 2021-03-01 | $43.59K 20-F · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |